Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sipponen

Showing results (441-450 of 459) with videos related to

Pageof 46
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 22, 2008
OLGA staging for gastritis: a tutorialM Rugge, P Correa, F Di Mario, et al.
Scandinavian Journal of Surgery : SJS : Official Organ for the Finnish Surgical Society and the Scandinavian Surgical Society|August 8, 2002
Endovascular treatment of aortic aneurysms in Finland: the first four years' experienceP S Aho, G Pimenoff, J P Salenius, et al.
Inflammatory Bowel Diseases|May 7, 2014
Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remissionPauliina Molander, Martti Färkkilä, Kimmo Salminen, et al.
Heliyon|July 8, 2024
Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatmentTero Ylisaukko-Oja, Clas-Göran Af Björkesten, Anja Eberl, et al.
Scandinavian Journal of Gastroenterology|January 17, 2012
Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkersLars Agréus, Ernst J Kuipers, Limas Kupcinskas, et al.
Journal of Crohn'S & Colitis|July 24, 2014
Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?Pauliina Molander, Martti Färkkilä, Ari Ristimäki, et al.
Scandinavian Journal of Gastroenterology|April 6, 2021
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in FinlandTaina Sipponen, Clas-Göran Af Björkesten, Taru Hallinen, et al.
Scandinavian Journal of Gastroenterology|June 12, 2019
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE)Anja Eberl, Taru Hallinen, Clas-Göran Af Björkesten, et al.
European Journal of Gastroenterology & Hepatology|February 19, 2025
Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort studyPauliina Molander, Clas-Göran Af Björkesten, Hans Henricson, et al.
Cancer Causes & Control : CCC|April 27, 2000
Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland)D Albanes, N Malila, P R Taylor, et al.
Pageof 46

Showing results (441-450 of 459) with videos related to

Sort By:
Pageof 46
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 22, 2008
OLGA staging for gastritis: a tutorialM Rugge, P Correa, F Di Mario, et al.
Scandinavian Journal of Surgery : SJS : Official Organ for the Finnish Surgical Society and the Scandinavian Surgical Society|August 8, 2002
Endovascular treatment of aortic aneurysms in Finland: the first four years' experienceP S Aho, G Pimenoff, J P Salenius, et al.
Inflammatory Bowel Diseases|May 7, 2014
Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remissionPauliina Molander, Martti Färkkilä, Kimmo Salminen, et al.
Heliyon|July 8, 2024
Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatmentTero Ylisaukko-Oja, Clas-Göran Af Björkesten, Anja Eberl, et al.
Scandinavian Journal of Gastroenterology|January 17, 2012
Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkersLars Agréus, Ernst J Kuipers, Limas Kupcinskas, et al.
Journal of Crohn'S & Colitis|July 24, 2014
Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?Pauliina Molander, Martti Färkkilä, Ari Ristimäki, et al.
Scandinavian Journal of Gastroenterology|April 6, 2021
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in FinlandTaina Sipponen, Clas-Göran Af Björkesten, Taru Hallinen, et al.
Scandinavian Journal of Gastroenterology|June 12, 2019
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE)Anja Eberl, Taru Hallinen, Clas-Göran Af Björkesten, et al.
European Journal of Gastroenterology & Hepatology|February 19, 2025
Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort studyPauliina Molander, Clas-Göran Af Björkesten, Hans Henricson, et al.
Cancer Causes & Control : CCC|April 27, 2000
Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland)D Albanes, N Malila, P R Taylor, et al.
Pageof 46